Ituri, DRC — A groundbreaking clinical trial for treating the Bundibugyo species of Ebola virus, which has been devastating the Democratic Republic of Congo (DRC), has commenced in the Ituri province.
The World Health Organization (WHO) reported the launch of the trial, which aims to evaluate the effectiveness of the monoclonal antibody MBP134 and the antiviral drug remdesivir.
The DRC’s Ebola outbreak has led to 1,406 confirmed cases, resulting in 438 deaths, and 208 recoveries.
The trial is sponsored by the WHO and is being coordinated by the Institut National de Recherche Biomédicale (INRB) in the DRC, the Institute of Tropical Medicine in Belgium, and the University of Oxford in the UK. Participants in the trial will receive comprehensive supportive care and close monitoring.
The research will also investigate the potential benefits of combining the two treatments. Supplies of MBP134 and remdesivir have been secured for up to 1,200 patients.
The trial is a critical step in combating the outbreak, which has been complicated by the ongoing conflict in the region. Despite the challenges, health workers and international organizations are collaborating to provide care and address the public health crisis.
The trial’s results could have significant implications for the treatment of future Ebola outbreaks, both in the DRC and globally.
As the trial gets underway, the world is closely monitoring the progress and potential impact of the new treatments.
*Additional reporting by ImNews | Sources consulted: 5*
—
This original article was produced by the ImNews editorial team
Source: Africanews
Source: AfricaNews
